Answers are grounded in this paper and cite their sources.
Retrospective study describes KRAS, NRAS, and BRAF mutation associations in stage IV colorectal cancer, suggesting personalized treatment implications.
149 Background: RAS and BRAF mutations play an important role in treatment selection and prognosis in metastatic colorectal cancer (mCRC). However, data on their clinical associations in Vietnamese patients remain limited. Objectives: To describe the clinical and subclinical characteristics and determine the mutation status of KRAS, NRAS, and BRAF genes in patients with stage IV colorectal cancer at Hanoi Medical University Hospital, and to explore their associations with selected clinical factors. Methods: This retrospective descriptive study included 144 patients with metastatic colorectal cancer and available KRAS, NRAS, and BRAF mutation results, treated between June 2023 and June 2025. Clinical, laboratory, and metastatic characteristics were collected and analyzed. Associations between mutation status and clinical variables were evaluated using appropriate statistical tests. Results: The mean age was 59.1 ± 13.5 years. Mutation rates were 39.6% for KRAS, 2.1% for NRAS, and 3.5% for BRAF, with 45.1% of patients harboring at least one RAS/BRAF mutation. KRAS mutation was significantly associated with right-sided primary tumors, tumor-related complications, elevated serum CEA (>20 ng/mL), bone metastasis, and more than five metastatic sites (all p < 0.05). No significant associations were observed between KRAS mutation and age, sex, ECOG performance status, histologic features, MSI status, or other metastatic characteristics. NRAS and BRAF mutations were not significantly associated with any evaluated clinical or paraclinical factors. Conclusions: KRAS mutation was identified in a substantial proportion of patients and was significantly associated with several adverse clinical features. These findings highlight the importance of routine molecular testing to support personalized treatment strategies in metastatic colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Linh Ly Tran (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: